(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 71.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Kura Oncology's revenue in 2025 is $67,991,000.On average, 6 Wall Street analysts forecast KURA's revenue for 2025 to be $17,505,401,711, with the lowest KURA revenue forecast at $2,545,295,798, and the highest KURA revenue forecast at $37,971,657,718. On average, 6 Wall Street analysts forecast KURA's revenue for 2026 to be $18,929,555,313, with the lowest KURA revenue forecast at $2,744,417,578, and the highest KURA revenue forecast at $39,062,498,774.
In 2027, KURA is forecast to generate $32,619,350,844 in revenue, with the lowest revenue forecast at $4,882,812,347 and the highest revenue forecast at $101,179,836,697.